Iovance Biotherapeutics Inc
300 Rouse Blvd
Philadelphia, PA 19102
Main Contact: Mr. Frederick Vogt, PhD, Esq.
Business Description:
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively.
Business Type:
Business Information:
- Established in 2007
- Publicly Owned
- Member Since 2020
